Friday, 27 March 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 27 March 2026
News

Aus pharma wins 20 year battle

Posted 24 November 2020

Perth-based Lawley Pharmaceuticals has been handed a TGA greenlight to commercialise its testosterone therapy for women experiencing sexual dysfunction -  a decision which was two decades in the making, the company's founder and CEO says.

Lawley's transdermal testosterone creme, AndroFeme 1, has been available from WA-based pharmacies since 1999 due to unique legislative differences between the the WA state government and the Commonwealth.

To see the whole article, please login

Popular

Company unveils role 'streamlining'
Why it's quitting time for pharma
Which pharmas are Most Ethical?
Novartis presses for cancer reform
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home